DUL:FRA
Alnylam Pharmaceuticals, Inc.
€206.20
arrow_downward
-0.67%(-1.40) 1D
Oct 20, 7:55:02 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€207.60
High
€210.10
Low
€206.20
Mkt. cap
30.83B
Avg. vol.
21.00
Volume
0.00
52-wk high
€423.00
52-wk low
€173.50
No. of employees
2K
Open
€207.60
High
€210.10
Low
€206.20
Mkt. cap
30.83B
Avg. vol.
21.00
Volume
0.00
52-wk high
€423.00
52-wk low
€173.50
No. of employees
2K
News stories
From web sources and news partners
Yahoo Finance
·
1 hour ago
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
ad-hoc-news.de
·
1 hour ago
Wells Fargo cuts Alnylam target to USD 253 for Alnylam Pharmaceuticals stock
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEOYvonne Greenstreet
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com